REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33.

2. Fantone S, Marzioni D, Tossetta G. NRF2/KEAP1 signaling inhibitors in gynecologic cancers. Expert Rev Anticancer Ther. 2024;24:1191-4.

3. Tan DSP, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7:925-34.

4. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273-82.

5. Worzfeld T, Pogge von Strandmann E, Huber M, et al. The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol. 2017;7:24.

6. Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186:1610-26.

7. Rodrigues G, Hoshino A, Kenific CM, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21:1403-12.

8. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113:143-8.

9. Reinartz S, Finkernagel F, Adhikary T, et al. A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 2016;17:108.

10. Iring A, Jin YJ, Albarrán-Juárez J, et al. Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure. J Clin Invest. 2019;129:2775-91.

11. Kiweler M, Looso M, Graumann J. MARMoSET - extracting publication-ready mass spectrometry metadata from RAW files. Mol Cell Proteomics. 2019;18:1700-2.

12. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26:1367-72.

13. Bhagwat A, Cotton R, Hayat S, et al. Autonomics: unified statistical modeling of omics data. 2025.

14. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.

15. Bortot B, Apollonio M, Rampazzo E, et al. Small extracellular vesicles from malignant ascites of patients with advanced ovarian cancer provide insights into the dynamics of the extracellular matrix. Mol Oncol. 2021;15:3596-614.

16. Cooper TT, Dieters-Castator DZ, Liu J, et al. Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer. J Ovarian Res. 2024;17:149.

17. Dorayappan KDP, Wagner V, Park D, et al. ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis. J Extracell Biol. 2024;3:e92.

18. Gu R, Jiang L, Dai S, Yue Y, et al. Identification of exosome-related SERPINB1 as a novel predictor for tumor immune microenvironment and clinical outcomes in ovarian cancer. J Ovarian Res. 2025;18:65.

19. Ferreira GA, Thomé CH, Izumi C, et al. Proteomic analysis of exosomes secreted during the epithelial-mesenchymal transition and potential biomarkers of mesenchymal high-grade serous ovarian carcinoma. J Ovarian Res. 2023;16:232.

20. Jo A, Green A, Medina JE, et al. Inaugurating high-throughput profiling of extracellular vesicles for earlier ovarian cancer detection. Adv Sci. 2023;10:e2301930.

21. Kong L, Xu F, Yao Y, Gao Z, et al. Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer. Front Oncol. 2023;13:1142755.

22. Vyhlídalová Kotrbová A, Gömöryová K, Mikulová A, et al. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer. J Extracell Vesicles. 2024;13:e12420.

23. Quiralte M, Barquín A, Yagüe-Fernández M, et al. Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer. J Clin Invest. 2024;134:e176161.

24. Runz S, Keller S, Rupp C, Stoeck A, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007;107:563-71.

25. Trinidad CV, Pathak HB, Cheng S, et al. Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer. Sci Rep. 2023;13:18341.

26. Wu J, Zeng D, Zhi S, Ye Z, et al. Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response. J Transl Med. 2021;19:381.

27. Yokoi A, Ukai M, Yasui T, Inokuma Y, et al. Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. Sci Adv. 2023;9:eade6958.

28. Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther. 2025;10:216.

29. Singh B, Fredriksson Sundbom M, Muthukrishnan U, et al. Extracellular histones as exosome membrane proteins regulated by cell stress. J Extracell Vesicles. 2025;14:e70042.

30. Palanissami G, Paul SFD. RAGE and its ligands: molecular interplay between glycation, inflammation, and hallmarks of cancer-a review. Horm Cancer. 2018;9:295-325.

31. Yin F, He Y, Qiao Y, Yan Y. Tumor-derived vesicles in immune modulation: focus on signaling pathways. Front Immunol. 2025;16:1581964.

32. Zhong Y, Wang Y, Wang C, et al. Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer. J Immunother Cancer. 2025;13:e011230.